| Literature DB >> 31878772 |
Su Hwan Kim1, Yun Jeong Lim2, Junseok Park3, Ki-Nam Shim4, Dong-Hoon Yang5, Jaeyoung Chun6, Jin Su Kim7, Hyun Seok Lee8, Hoon Jai Chun9.
Abstract
BACKGROUND/AIMS: Capsule endoscopy (CE) is widely used for the diagnosis of small bowel diseases. The clinical performance and complications of small bowel CE, including completion rate, capsule retention rate, and indications, have been previously described in Korea. This study aimed at estimating the recent changes in clinical performance and complications of small bowel CE based on 17-year data from a Korean Capsule Endoscopy Registry.Entities:
Keywords: Bowel preparation; Capsule endoscopy; Intestine, small; Retention
Mesh:
Year: 2019 PMID: 31878772 PMCID: PMC7373959 DOI: 10.3904/kjim.2019.312
Source DB: PubMed Journal: Korean J Intern Med ISSN: 1226-3303 Impact factor: 2.884
Demographic information and incomplete examination and retention rates
| Variable | Total | ~Aug. 31, 2014 | Sep. 1, 2014~ |
|---|---|---|---|
| Age | 53.5 ± 18.8 | 53.1 ± 18.1 | 55.0 ± 20.5 |
| Male sex | 2,804 (60.3) | 2,067 (61.1) | 681 (58.2) |
| Incompletion | 678 (16.3) | 570 (18.9) | 108 (9.4)[ |
| Retention | 125 (3.0) | 105 (3.2) | 20 (2.6) |
Values are presented as mean ± SD or number (%).
Decreased trend.
Indications for capsule endoscopy
| Variable | Total | ~Aug. 31, 2014 | Sep. 1, 2014~ |
|---|---|---|---|
| Obscure GI bleeding | 2,965 (64.4) | 2,110 (62.7) | 790 (68.8)[ |
| Overt | 2,445 (53.1) | 1,755 (52.2) | 638 (55.6) |
| Occult | 520 (11.3) | 355 (10.5) | 152 (13.2) |
| Abdominal pain | 724 (15.7) | 594 (17.7) | 117 (10.2) |
| Crohn’s disease | 212 (4.6) | 119 (3.5) | 86 (7.5)[ |
| Small bowel tumor | 166 (3.6) | 122 (3.6) | 42 (3.7) |
| Chronic diarrhea | 171 (3.7) | 118 (3.5) | 51 (4.4) |
| Weight loss | 19 (0.4) | 18 (0.5) | 1 (0.1) |
| Cancer of unknown primary site | 4 (0.1) | 3 (0.1) | 0 |
| Protein-losing enteropathy | 15 (0.3) | 6 (0.2) | 7 (0.6) |
| Behcet’s disease, TB enteritis | 44 (1.0) | 21 (0.6) | 23 (2.0) |
| Ileus | 13 (0.3) | 5 (0.1) | 8 (0.7) |
| Screening | 214 (4.6) | 209 (6.2) | 2 (0.2) |
Values are presented as number (%).
GI, gastrointestinal; TB, tuberculous.
Increased trend.
Capsule endoscopic diagnosis
| Variable | Total | ~Aug. 31, 2014 | Sep. 1, 2014~ |
|---|---|---|---|
| Normal | 1,647 (36.2) | 1,285 (38.5) | 322 (28.4)[ |
| Vascular lesions | |||
| Angiodysplasia, telangiectasia, Dieulafoy’s lesion | 442 (9.7) | 349 (10.4) | 87 (7.7) |
| Bleeding of unidentified origin | 234 (5.1) | 122 (3.7) | 109 (9.6) |
| Varices | 12 (0.3) | 10 (0.3) | 2 (0.2) |
| Inflammatory lesions | |||
| Erosion, not signified | 365 (8.0) | 233 (7) | 130 (11.5) |
| Ulcer, not signified | 469 (10.3) | 352 (10.5) | 112 (9.9) |
| Hemorrhagic enteropathy | 31 (0.7) | 28 (0.8) | 3 (0.3) |
| Congestive enteropathy | 13 (0.3) | 13 (0.4) | 6 (0.5) |
| H-S purpura, vasculitis | 11 (0.2) | 10 (0.3) | 1 (0.1) |
| Ischemic enteritis | 9 (0.2) | 6 (0.2) | 3 (0.3) |
| NSAID enteropathy | 267 (5.9) | 190 (5.7) | 74 (6.5) |
| TB enteritis | 30 (0.7) | 16 (0.5) | 12 (1.1) |
| Behcet’s enteritis | 33 (0.7) | 22 (0.7) | 11 (1.0) |
| Radiation enteritis | 9 (0.2) | 8 (0.2) | 0 |
| Eosinophilic enteritis | 18 (0.4) | 10 (0.3) | 6 (0.5) |
| Crohn’s disease | 316 (6.9) | 211 (6.3) | 96 (8.5)[ |
| CMUSE | 3 (0.1) | 1 (0) | 2 (0.2) |
| Tumor lesions | |||
| Lymphoid hyperplasia | 25 (0.5) | 22 (0.7) | 3 (0.3) |
| Lymphangiectasia | 30 (0.7) | 17 (0.5) | 12 (1.1) |
| Malignant tumor | 50 (1.1) | 40 (1.2) | 9 (0.8) |
| Submucosal tumor | 146 (3.2) | 120 (3.6) | 24 (2.1) |
| Polyp, adenomatous | 25 (0.5) | 21 (0.6) | 4 (0.4) |
| Polyp, non-neoplastic | 134 (2.9) | 105 (3.1) | 25 (2.2) |
| Peutz-Jeghers syndrome | 10 (0.2) | 7 (0.2) | 3 (0.3) |
| Hemangioma | 4 (0.1) | 2 (0.1) | 2 (0.2) |
| Lymphangioma | 3 (0.1) | 2 (0.1) | 1 (0.1) |
| Others | 220 (4.8) | 138 (4.1) | 82 (7.2) |
Values are presented as number (%).
H-S, Henoch–Schönlein; NSAID, nonsteroidal anti-inflammatory drug; TB, tuberculous; CMUSE, cryptogenic multifocal ulcerous stenosing enteritis.
Decreased trend.
Increased trend.
Factors associated with incomplete examination
| Variable | Crude | Age and sex adjusted | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 1.005 | 1.001–1.009 | 0.026 | |||
| Male sex | 0.911 | 0.771–1.076 | 0.274 | |||
| Indication for capsule endoscopy | ||||||
| OGIB vs. others | 0.761 | 0.642–0.902 | 0.002 | 0.712 | 0.597–0.850 | < 0.001 |
| Crohn’s disease vs. others | 0.864 | 0.574–1.301 | 0.484 | 0.966 | 0.636–1.467 | 0.871 |
| Small bowel tumor vs. others | 0.827 | 0.523–1.308 | 0.418 | 0.868 | 0.548–1.375 | 0.548 |
| Bowel preparation | ||||||
| Inadequate vs. adequate | 1.757 | 1.479–2.086 | < 0.001 | 1.750 | 1.472–2.080 | < 0.001 |
OR, odds ratio; CI, confidence interval; OGIB, obscure gastrointestinal bleeding.
Factors associated with capsule retention
| Variable | Crude | Age and sex adjusted | ||||
|---|---|---|---|---|---|---|
| OR | 95% CI | OR | 95% CI | |||
| Age | 0.999 | 0.989–1.008 | 0.814 | |||
| Male sex | 0.83 | 0.580–1.188 | 0.309 | |||
| Indication for capsule endoscopy | ||||||
| OGIB vs. others | 1.083 | 0.745–1.575 | 0.677 | 1.092 | 0.743–1.604 | 0.654 |
| Crohn’s disease vs. others | 2.264 | 1.226–4.182 | 0.009 | 2.380 | 1.258–4.505 | 0.008 |
| Small bowel tumor vs. others | 0.213 | 0.030–1.533 | 0.124 | 0.209 | 0.029–1.506 | 0.120 |
| Bowel preparation | ||||||
| Inadequate vs. adequate | 2.434 | 1.677–3.533 | < 0.001 | 2.412 | 1.657–3.510 | < 0.001 |
OR, odds ratio; CI, confidence interval; OGIB, obscure gastrointestinal bleeding.
Capsule retention rates according to indications for capsule endoscopy
| Indications of capsule endoscopy | No. (%) |
|---|---|
| Obscure GI bleeding | 82 (3.1) |
| Abdominal pain | 20 (3.0) |
| Crohn’s disease | 12 (6.3) |
| Small bowel tumor | 1 (0.7) |
| Screening | 0 |
| Chronic diarrhea | 2 (1.3) |
GI, gastrointestinal.
Bowel preparation quality according to bowel preparation method
| Variable | NPO | PEG 4 L | PEG 2 L | PEG + Asc 2 L | NaP | |
|---|---|---|---|---|---|---|
| Quality | < 0.001 | |||||
| Excellent | 149 (21.4) | 104 (16.1) | 165 (10.8) | 92 (13.5) | 89 (30.3) | |
| Good | 340 (48.9) | 388 (60.1) | 874 (57.5) | 289 (42.6) | 138 (46.9) | |
| Fair | 161 (23.2) | 119 (18.4) | 368 (24.2) | 215 (31.7) | 53 (18.0) | |
| Poor | 45 (6.5) | 35 (5.4) | 114 (7.5) | 83 (12.2) | 14 (4.8) | |
| Acceptability | < 0.001 | |||||
| Adequate | 489 (70.4) | 492[ | 1,039 (68.3) | 381[ | 227[ | |
| Inadequate | 206 (29.6) | 154 (23.8) | 482 (31.7) | 298 (43.9) | 67 (22.8) | |
| Reference | 0.017 | 0.333 | < 0.001 | 0.028 |
Values are presented as number (%).
NPO, nil per os; PEG, polyethylene glycol; Asc, ascorbic acid; NaP, sodium phosphate.
Statistically significant in comparison with NPO (p < 0.05).
Trends in bowel preparation methods
| Variable | Total | ~Aug. 31, 2014 | Sep. 1, 2014~ |
|---|---|---|---|
| NPO | 704 (17.5) | 560 (19.2) | 144 (12.9) |
| PEG 4 L | 658 (16.3) | 546 (18.7) | 111 (10.0) |
| PEG 2 L | 1,553 (38.5) | 1,398 (47.9) | 155 (13.9) |
| PEG + Asc 2 L | 681 (16.9) | 34 (1.2) | 646 (58.1) |
| NaP | 297 (7.4) | 297 (10.2) | 0 |
| Picosulfate | 64 (1.6) | 8 (0.3) | 56 (4.8) |
| Others | 77 (1.9) | 77 (2.7) | 0 |
Values are presented as number (%).
NPO, nil per os; PEG, polyethylene glycol; Asc, ascorbic acid; NaP, sodium phosphate.